Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action.

Autor: Sophie Hallakou-Bozec, Micheline Kergoat, Pascale Fouqueray, Sébastien Bolze, David E Moller

Publikováno v: PLoS ONE, Vol 16, Iss 2, p e0241651 (2021)

Pancreatic islet β-cell dysfunction is characterized by defective glucose-stimulated insulin secretion (GSIS) and is a predominant component of the pathophysiology of diabetes. Imeglimin, a novel first-in-class small molecule tetrahydrotriazine drug

Externí odkaz: https://doaj.org/article/252dbd8ec96f47f7ab59bc8d28490a5c

Islet endothelial activation and oxidative stress gene expression is reduced by IL-1Ra treatment in the type 2 diabetic GK rat.

Autor: Grégory Lacraz, Marie-Hélène Giroix, Nadim Kassis, Josiane Coulaud, Anne Galinier, Christophe Noll, Mélanie Cornut, Fabien Schmidlin, Jean-Louis Paul, Nathalie Janel, Jean-Claude Irminger, Micheline Kergoat, Bernard Portha, Marc Y Donath, Jan A Ehses, Françoise Homo-Delarche

Publikováno v: PLoS ONE, Vol 4, Iss 9, p e6963 (2009)

BACKGROUND:Inflammation followed by fibrosis is a component of islet dysfunction in both rodent and human type 2 diabetes. Because islet inflammation may originate from endothelial cells, we assessed the expression of selected genes involved in endot

Externí odkaz: https://doaj.org/article/ca414e1d4d7746b08c0a66e000e93147

Kynurenine-3-monooxygenase expression is activated in the pancreatic endocrine cells by diabetes and its blockade improves glucose-stimulated insulin secretion

Autor: Junjun Liu, Danielle Bailbé, Sophie Raynal, Christel Carbonne, Delong Zhen, Julien Dairou, Blandine Gausseres, Mathieu Armanet, Thomas Domet, Caterina L. Pitasi, Jamileh Movassat, Chai K. Lim, Gilles J. Guillemin, Valérie Autier, Micheline Kergoat, Bernard Portha

Publikováno v: Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1868:166509

Type 2 diabetes is associated with an inflammatory phenotype in the pancreatic islets. We previously demonstrated that proinflammatory cytokines potently activate the tryptophan/kynurenine pathway (TKP) in INS-1 cells and in normal rat islets. Here w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::966a2fe2156ffb6935197684b4274ea5
https://doi.org/10.1016/j.bbadis.2022.166509

Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes

Autor: Guillaume Vial, Sébastien Bolze, Anne-Laure Borel, David E. Moller, Eric Fontaine, Sophie Hallakou-Bozec, Pascale Fouqueray, Micheline Kergoat

Publikováno v: Diabetes, Obesity and Metabolism
Diabetes, Obesity and Metabolism, 2021, 23 (3), pp.664-673. ⟨10.1111/dom.14277⟩
Diabetes, Obesity & Metabolism

International audience; Imeglimin is an investigational first-in-class novel oral agent for the treatment of type 2 diabetes (T2D). Several pivotal phase III trials have been completed with evidence of statistically significant glucose lowering and a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3db5a4ad2135f34886f819e394773a4
https://www.hal.inserm.fr/inserm-03666043

Low Intensity Extracorporeal Shock Wave Therapy Improves Erectile Function in a Model of Type II Diabetes Independently of NO/cGMP Pathway

Autor: Yoram Vardi, J. Bernabé, Diane Gorny, Rana Assaly-Kaddoum, Micheline Kergoat, Miguel Laurin, François Giuliano, Delphine Behr-Roussel, Laurent Alexandre

Publikováno v: Journal of Urology. 196:950-956

Erectile dysfunction is highly prevalent in type II diabetes mellitus. Low intensity extracorporeal shock wave therapy improves erectile function in patients with erectile dysfunction of vasculogenic origin, including diabetes. However, its mode of a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::825418538f331b899d9b3a487bf27fad
https://doi.org/10.1016/j.juro.2016.03.147